28/February/2022 Top Medical Bulletin

Published On 2022-02-28 13:15 GMT   |   Update On 2022-02-28 13:15 GMT

Here are top medical stories for todayGlucose Variability During Early Course Of Acute Pancreatitis Can Predict New-Onset Of Diabetes Diabetes is a serious metabolic disorder that causes severe health issues. Its most common subtype, post-pancreatitis diabetes mellitus, is associated with a 13% higher risk of all-cause mortality than type 2 diabetes. Acute pancreatitis (AP) is the...

Login or Register to read the full article

Here are top medical stories for today

Glucose Variability During Early Course Of Acute Pancreatitis Can Predict New-Onset Of Diabetes

Diabetes is a serious metabolic disorder that causes severe health issues. Its most common subtype, post-pancreatitis diabetes mellitus, is associated with a 13% higher risk of all-cause mortality than type 2 diabetes. Acute pancreatitis (AP) is the largest contributor to diabetes of the exocrine pancreas. The study findings published in the United European Gastroenterology Journal on February 20, 2022 report that glucose variability (GV) during hospitalisation for acute pancreatitis accurately predicts future risk of developing deranged glucose metabolism, including new-onset diabetes after acute pancreatitis.

For more information check out the full story on the link below:

Glucose Variability During Early Course Of Acute Pancreatitis Can Predict New-Onset Of Diabetes

Air pollution exposure in kids to be a risk factor for Attention Deficit Hyperactivity Disorder

Pollution is a serious concern despite several awareness camps pollution continues to top the list of health risks. Children with Attention Deficit Hyperactivity Disorder (ADHD) commonly have trouble paying attention, controlling impulsive behaviors or be overly active. Study published in Environment International journal says children living in areas with higher air pollution and lower level of green space might have up to 62 per cent increased risk of developing Attention Deficit Hyperactivity Disorder.

House dust mite sublingual immunotherapy effective for allergic asthma

Asthma affects quality of life to a greater extent, but house dust mite sublingual immunotherapy may be effective for allergic asthma, according to a recent study published in the Journal of Allergy and Clinical Immunology: In Practice.

House dust mite sublingual immunotherapy (HDM SLIT) effectively treats allergic rhinitis (AR). However, the evidence of HDM SLIT for allergic asthma remained limited. A study was conducted to systematically review the efficacy and safety of HDM SLIT tablets in patients with allergic asthma.

For more information check out the full story on the link below:

House dust mite sublingual immunotherapy effective for allergic asthma: Study

The CREDENCE trial: Canagliflozin does not impact risk of neuropathy events in diabetics

Diabetic neuropathy being the most common complication, High blood sugar (glucose) can injure nerves throughout your body..A post-hoc exploratory analysis of the CREDENCE trial has revealed that canagliflozin, a SGLT2 inhibitor, did not affect the risk of neuropathy. The findings of the study were published in the journal Diabetes & Metabolism. The trial included included patients with type 2 diabetes and kidney disease. They were randomized to receive canagliflozin 100mg daily or placebo. Neuropathy events were defined post-hoc as any reported adverse event consistent with a peripheral or autonomic neuropathy event. The results showed that the incidence of neuropathy events was similar in people randomized to canagliflozin and placebo. Canagliflozin had no impact on sensorimotor polyneuropathy, diabetic neuropathy, or non-autonomic neuropathy. The trial then further concluded, canagliflozin did not affect the risk of neuropathy events in the CREDENCE trial. 

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News